🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

150 results for “chemotherapy” Clear

  1. neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  2. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  3. A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  4. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  5. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  6. Avatrombopag

    Hospital Authority, Hong Kong

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  7. B-MAD chemotherapy

    Takeda

    Extranodal NK/T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  8. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  9. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  10. CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.

    phase 2 small molecule active

    1 trial

  11. Chemotherapy + immunotherapy

    Hunan Province Tumor Hospital

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Chemotherapy plus apatinib

    Lei Li

    Recurrent Cervical Carcinoma

    phase 2 small molecule completed

    1 trial

  13. Chemotherapy+PD-1 inhibitor+8Gy x 3f

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HR+HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  14. Chidamide + Tislelizumab + chemotherapy (CapeOX )

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  16. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  17. Eltrombopag

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  18. First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)

    Pari Pharma GmbH

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    phase 2 other active

    1 trial

  19. Forxiga 10 mg film-coated tablets

    Fondazione Telethon ETS

    Chemotherapy-induced cardiotoxicity in breast cancer

    phase 2 small molecule active

    1 trial

  20. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  21. Furmonertinib in combination with Anrotinib and chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  22. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  23. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  24. Halneuron

    Dogwood Therapeutics

    Chemotherapy Induced Neuropathic Pain

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources